The Lung Microbiome in Sarcoidosis

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT02520323

Enrollment

Registered

2015-08-11

Start date

2015-06-30

Completion date

2017-06-30

Last updated

2017-06-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Sarcoidosis

Brief summary

The objective of this study is to determine the presence of bacterial species, and the immunologic and molecular mechanisms of granuloma formation that might be involved in the pathogenesis of sarcoidosis. The investigators will collect peripheral blood and bronchoalveolar lavage fluid samples to isolate bacterial DNA and blood monocytes and lymphocytes. Specimens will be obtained from patients with sarcoidosis, with non-sarcoid lung disease, and healthy volunteers to directly compare the bacterial species present and the characteristics of cells thought to be involved in granuloma formation.

Interventions

OTHERBlood draw

PROCEDUREBronchoscopy

BEHAVIORALQuestionnaires

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

30 Years to 60 Years

Healthy volunteers

Yes

Inclusion criteria

* Clinical diagnosis of sarcoidosis (30 subjects) or * Clinical diagnosis of non-sarcoid interstitial lung disease (10 subjects) or * Age-matched controls (30 subjects) * Ability to provide informed consent

Exclusion criteria

* Any disease condition (such as anemia, unstable cardiac disease, etc.) that in the opinion of the subject's primary physician would put the patient at risk of harm from having 60 cc of blood drawn or for undergoing bronchoscopy for this study. * Patients who are undergoing bronchoscopy for presumed infection. * Pregnant women, women who may be pregnant, and women who are breastfeeding. * Patients who have undergone lung transplantation. * Persons who are unable or unwilling to undergo bronchoscopy, including those unable to be accompanied by a designated driver to the procedure. * Persons who have taken antibiotics in the 90 days prior to consent. * Known HIV, HCV, alcohol, or other substance abuse history.

Design outcomes

Primary

Measure	Time frame	Description
Microbiome analysis	Baseline	To assess the microbiome profile in lung lavage fluid and peripheral blood of subjects

Secondary

Measure	Time frame	Description
Measures of immunologic phenotype	Baseline	To determine whether the immune cell profile of sarcoidosis patients differs from healthy controls and other interstitial lung disease patients in blood and BAL fluid

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026